Comparative application of derivative spectrophotometric and HPLC techniques for the simultaneous determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combined drugs
Abstract Background Lamivudine (LAM) and tenofovir disoproxil fumarate (TDF) are part of a fixed-dose combination (FDC) therapy recommended by WHO. Both drugs exhibit similar solubility in many solvent systems and tend to have overlapping spectra with maxima at 260 and 270 nm, respectively, in the U...
Main Authors: | Edebi N. Vaikosen, Samuel J. Bunu, Jude N. Oraeluno, David Friday |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-03-01
|
Series: | Future Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43094-023-00471-7 |
Similar Items
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01) -
The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01) -
Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Kubra Kurt, et al.
Published: (2016-06-01) -
Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice
by: Eungyeong Jang, et al.
Published: (2020-10-01) -
Early switching of tenofovir disoproxil fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study
by: Samadhi Patamatamkul, et al.
Published: (2022-12-01)